Back to Alzheimers Disease
NCT02972658
NCT02972658
Who may be able to join
Who might be able to join this trial:
- You must have already taken part in a previous clinical trial called AMARANTH (NCT02245737) and still meet the requirements to continue into this new phase of the study.
Who may not be able to join:
- If you were part of the AMARANTH trial (NCT02245737) but have since developed any new health conditions that would prevent you from safely joining this follow-on study, you would not be eligible (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Terminated
Phase
Phase 3
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
15 March 2017
Est. completion
2 October 2018
Where this trial is recruiting
🇦🇺 Australia
🇧🇪 Belgium
🇨🇦 Canada
🇫🇷 France
🇩🇪 Germany
🇭🇺 Hungary
🇯🇵 Japan
🇵🇱 Poland
Puerto Rico
🇷🇴 Romania
🇰🇷 South Korea
🇪🇸 Spain
🇬🇧 United Kingdom
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.